Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor ...

Vertex Flooring introduces distinctive marquetry flooring crafted with expert precision, offering custom wood designs ...

With a market cap of $116.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on ...

ClearBridge Investments, an investment management company, released its “ClearBridge Growth Strategy” fourth-quarter 2025 ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...

Detailed price information for Vertex Inc Cl A (VERX-Q) from The Globe and Mail including charting and trades.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks ...

Just a week after Vertex’s stem cell therapy to treat type 1 diabetes was released from an FDA clinical hold, the company is clearing out potential competition by buying ViaCyte for $320 million. The ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek and its non-opioid pain relief ...